Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | PARP1 | P09874 | 2/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.42 |
| ▸ | SRD5A1 | P18405 | 7/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TYMS | P04818 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3267926 | 0.92 | CYP2A6 (0.54) | CYP2A6CYP1A2CYP3A4CYP2C9CYP11B1 | |
| SCHEMBL12430513 | 0.88 | NPC1 (0.42) | CYP2A6CYP1A2CYP3A4CYP2C9CYP11B1 | |
| SCHEMBL6584253 | 0.85 | CYP1A2 (0.50) | CYP2A6CYP1A2CYP2C19PARP1PARP10 | |
| SCHEMBL6936889 | 0.80 | NPC1 (0.42) | CYP2A6PARP1PARP10NOTUMACHE | |
| SCHEMBL8342556 | 0.79 | — | — | |
| SCHEMBL3267412 | 0.76 | CYP2A6 (0.48) | CYP2A6CYP1A2CYP3A4CYP2C9CYP11B1 | |
| SCHEMBL266510 | 0.75 | CYP2A6 (0.54) | CYP2A6CYP1A2CYP3A4CYP2C9CYP11B1 | |
| SCHEMBL1701852 | 0.75 | CYP2A6 (0.54) | CYP2A6CYP1A2CYP3A4CYP2C9CYP11B1 | |
| SCHEMBL354022 | 0.75 | CYP2A6 (0.54) | CYP2A6CYP1A2CYP3A4CYP2C9CYP11B1 | |
| SCHEMBL588130 | 0.75 | CYP2A6 (0.54) | CYP2A6CYP1A2CYP3A4CYP2C9CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036628-A | Iron death inhibitor, preparation method and application thereof | 福建医科大学 | 2026-05-15 | — | — | CN | disclosed |
| US-20250326764-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS LLC (US) | 2025-10-23 | — | — | US | disclosed |
| US-12312359-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2025-05-27 | — | — | US | disclosed |
| WO-2025077767-A1 | NOVEL I-TYPE TOPOISOMERASE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翊维康医药有限责任公司 | 2025-04-17 | — | — | WO | disclosed |
| CN-114075141-B | Opioid receptor \"bias\" ligand, preparation method and medical application thereof | 上海致根医药科技有限公司 | 2025-02-25 | — | — | CN | disclosed |
| US-20230174541-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, LLC | 2023-06-08 | — | — | US | disclosed |
| US-RE49481-E1 | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease | HOFFMANN-LA ROCHE INC. (US) | 2023-04-04 | — | — | US | disclosed |
| US-11479557-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2022-10-25 | — | — | US | disclosed |
| US-20220281863-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | REVERIE LABS INC (US) | 2022-09-08 | — | — | US | disclosed |
| CN-114075141-A | Opioid receptor 'bias' ligand, preparation method and application thereof in medicine | 上海致根医药科技有限公司 | 2022-02-22 | — | — | CN | disclosed |
| US-4883815-A | CONTROL OR PREVENTION OF CEREBRAL INSUFFICIENCY, IMPROVEMENT OF COGNITIVE FUNCTIONS | HOFFMANN-LA ROCHE INC. (US) | 1989-11-28 | — | — | US | disclosed |
| CN-1036952-A | Hydrogenated cinnamic acid derivative and its method for making | HOFFMANN LA ROCHE (CH) | 1989-11-08 | — | — | CN | disclosed |
| US-4876340-A | Benzazecine derivatives for cognitive and memory functions | HOFFMANN-LA ROCHE INC. (US) | 1989-10-24 | — | — | US | disclosed |
| EP-0300371-A1 | Hydrocinnamic acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1989-01-25 | — | — | EP | disclosed |
| US-4749791-A | Benzo[f]quinoline intermediates | HOFFMANN-LA ROCHE INC. (US) | 1988-06-07 | — | — | US | disclosed |
| US-4732979-A | CEREBRAL INSUFFICIENCY | HOFFMANN-LA ROCHE INC. (US) | 1988-03-22 | — | — | US | disclosed |
| EP-0230967-A2 | Benzazecine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1987-08-05 | — | — | EP | disclosed |
| EP-0063418-B1 | INDANYLOXY- AND TETRALINYLOXY-PHENOXYPROPIONIC ACID DERIVATIVES, PROCESSES FOR PREPARING THEM, AND HERBICIDAL PROCESSES AND COMPOSITIONS UTILISING THEM | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-10-03 | — | — | EP | disclosed |
| US-4431834-A | INDAN OR TETRALIN DERIVATIVES; PLANT GROWTH REGULATORS; GRASSES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-02-14 | — | — | US | disclosed |
| EP-0063418-A1 | Indanyloxy- and tetralinyloxy-phenoxypropionic acid derivatives, processes for preparing them, and herbicidal processes and compositions utilising them | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1982-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174541-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | CYP2A6 4370/4885CYP1A2 4596/4885CYP3A4 4408/4885 |
| US-20220281863-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CDK9, CDK19, CDK6 | CYP2A6 1988/4885CYP1A2 3348/4885CYP3A4 3254/4885 |
| US-12312359-B2 | Inhibitors of the menin-MLL interaction | MLLT1, MEN1, MLLT3 | CYP2A6 4370/4885CYP1A2 4596/4885CYP3A4 4408/4885 |
| US-11479557-B2 | Inhibitors of the menin-MLL interaction | MLLT1, MEN1, MLLT3 | CYP2A6 4370/4885CYP1A2 4596/4885CYP3A4 4408/4885 |
| US-20250326764-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | CYP2A6 4370/4885CYP1A2 4596/4885CYP3A4 4408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.